Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021383 | 0.83 | ADORA1 (0.59) | ADORA1ADORA2AGRM4LMNA | |
| SCHEMBL21121007 | 0.83 | KMT2A (0.47) | ADORA1ADORA2AKMT2AMAP3K14MAPK14 | |
| SCHEMBL29539989 | 0.81 | CYP2A6 (0.57) | ADORA1ADORA2ACDK5CDK5R1ALOX5AP | |
| SCHEMBL21121008 | 0.80 | ADORA1 (0.42) | ADORA1ADORA2AKMT2AMAP3K14MAPK14 | |
| SCHEMBL5449788 | 0.79 | ADORA1 (0.87) | ADORA1ADORA2ACDK5CDK5R1KMT2A | |
| SCHEMBL13828676 | 0.78 | NPC1 (0.44) | ADORA1ADORA2AKMT2AMAPK14LMNA | |
| SCHEMBL13829027 | 0.78 | MAPK14 (0.40) | ADORA1ADORA2AMAPK14LMNA | |
| SCHEMBL21121012 | 0.77 | KMT2A (0.43) | ADORA1ADORA2AKMT2AMAP3K14MAPK14 | |
| SCHEMBL28406688 | 0.77 | DHFR (0.56) | ADORA1ADORA2AKMT2AMAP3K14RPS6KA3 | |
| SCHEMBL31339965 | 0.77 | KMT2A (0.71) | ADORA1ADORA2AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-12-09 | — | — | US | disclosed |
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-12-09 | — | — | US | disclosed |
| WO-2009055418-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-4512993-A | 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | PIKFYVE, JAK3, PI4KA | ADORA1 940/4885ADORA2A 1079/4885CDK5 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.